GSK joins up with Aspen in Japanese venture; Roche's Lucentis on fast track for new diabetic retinopathy use;

@FiercePharma: Top-read in FP Weds: Novartis, GSK shake up executive ranks as overhaul continues. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI, this week's issue of FiercePharmaMarketing is here. And you can subscribe here. | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) inked a deal with South Africa-based Aspen Pharmacare to market mature products and new authorized generics in Japan. Report

> Roche's ($RHHBY) eye drug Lucentis won priority review at the FDA for a new use in diabetic retinopathy. Release

> Bristol-Myers Squibb ($BMY) said it has settled all U.S. patent litigation on its HIV drug Sustiva, giving the drug exclusivity through December 2017. Release

> Hospira ($HSP) recalled one lot of the high-powered antibiotic vancomycin because of potential temperature changes that could have affected the drug. Release

> India's Cipla said it would collaborate with Teva Pharmaceuticals ($TEVA) to sell Teva's drugs in South Africa, via a subsidiary, Medpro Pharmaceuticals. Report

> A headhunting firm sued Novartis Consumer Health ($NVS) for breach of contract, saying the drugmaker avoided paying $578,000 owed for executive search services. Report (reg. req.)

> Ironwood Pharmaceuticals ($IRWD) and Actavis ($ACT) are rolling out data on their gastrointestinal drug linaclotide, sold as Linzess in the U.S. and Constella in the EU. Release

Medical Device News

@FierceMedDev: Histogenics files for IPO, as Autogenomics refiles again. Article | Follow @FierceMedDev

@VarunSaxena2: HillaryClinton says we have to review +s and -s of device tax. An expected non-answer. | Follow @VarunSaxena2

@EmilyWFierce: Third time's a charm? FDA panel recommends Boston Scientific's Watchman device by a slim margin. More from the WSJ | Follow @EmilyWFierce

@MichaelGFierce: With $RHHBY's Herceptin, green tea component doubles drug accumulation in #cancer cells. More | Follow @MichaelGFierce

> Boston Scientific wins positive recommendation from FDA panel for stroke-fighting Watchman device. More

> Stealth surgical reconstruction startup Tela-Bio raises $45.4 million. Item

> CoheroHealth to pilot asthma inhaler sensor and app at Mount Sinai Medical Center. Article

Biotech News

@FierceBiotech: VC giant NEA recruits a biotech vet to join its ranks of dealmakers. Report | Follow @FierceBiotech

@JohnCFierce: Biotechs tap a swelling tide of investment cash to fund growing R&D ops--or, laissez les bon temps rouler. Story | Follow @JohnCFierce

@DamianFierce: Deal: $AUXL leaves $QLTI at the altar and accepts a $2.6B offer from $ENDP. Release | Follow @DamianFierce

@EmilyMFierce: Ebola genome browser launched to aid drug discovery. FierceBiotech Research story | Follow @EmilyMFierce

> Auxilium takes money, runs from inversion with $2.6B Endo deal. Report

> Shire's long-delayed ADHD drug hits another FDA speed bump. Article

Vaccines News

> Pfizer's meningitis B vaccine is effective when given with HPV jab. More

> Sanofi bird flu vax prompts immune response in PhII--but only with Novartis adjuvant. Story

> Biotechs angling for T-cell response in race for next-gen herpes vaccine. Article

> Takeda appoints new vax development head as Novartis' Oswald heads for the door. Report

> Could 'space bacteria' help create vaccines? Item

Pharma Manufacturing News

> Impax says $700M deal for Tower will help it deal with quality issues. More

> Hospira recalls drug because of storage glitch during shipping. Report

> France's Ceva has completed a sterile facility for vet drugs. Item

> Gerresheimer adjusts earnings forecast lower in wake of FDA crackdown. Article

> CSL announces $450M commitment to expand two of its plants. Story

And Finally... More states are allowing preschools to mandate flu vaccinations for their charges. Report (sub. req.)

Suggested Articles

AstraZeneca and Brazil have expanded their deal for a possible COVID-19 vaccine, this time to the tune of $360 million.

Novavax expects to churn out enough vaccines in 2021 to meet U.S. demand; experts slam the medical and political risks of Russia's unproven vaccine.

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.